Novavax's R&D program paved way for a protein-based COVID-19 vaccine, with 1 Mn+ doses administered
Register to read the full analysis —or— Upgrade to access more features
#R&D
#Research and Development
#Vaccines
#vaccination
#covid pandemic
Actual Direct Impact
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.